Skip to main content
3d rendering of Human cell
Anusorn - stock.adobe.com

Kapellos Lab

Immunoregulation in obstructive airway diseases

The Kapellos Lab investigates the heterogeneity in structure and functions of human lung immune cells, primarily myeloid cells, to better understand the inflammatory mechanisms that drive the initiation and development of obstructive airway diseases.

The Kapellos Lab investigates the heterogeneity and functions of human immune cells, particularly myeloid cells, in order to better understand the inflammatory mechanisms that drive the initiation and progression of obstructive lung diseases.

The immune system plays a pivotal role in obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis and allergic asthma which are characterized by chronic inflammation and structural changes in the airways. Immune cells are involved in mediating and modulating these processes by responding to various environmental triggers, e.g. inhaled pollutants or allergens and promote irreversible inflammation and lung tissue damage. Understanding the intricate interactions between immune cells and the respiratory system is essential for revealing the underlying mechanisms of disease progression from the initial stages to more advanced manifestations and insights into immune responses are crucial for identifying therapeutic targets and designing novel drugs.

Our laboratory is dedicated to the exploration of obstructive airway diseases with a primary objective to unravel the contributions of the immune system to the progression of these diseases, spanning from early to advanced stages. Our goal is to identify cellular pathways that can be targeted to alleviate disease manifestations and to improve clinical outcome and patient quality of life. Central to our approach is a keen appreciation for patient diversity. Consequently, we meticulously assess the molecular heterogeneity of prospective clinical cohorts affected by obstructive airway diseases. This in-depth understanding aids us in expediting the design of novel personalized therapeutics.

In our research, we employ a dual-pronged strategy. We utilize cutting-edge single-cell transcriptomics technologies and computational analysis to define immune molecular phenotypes relevant to disease. Additionally, in 2024, we plan to incorporate microbiome analysis through 16S rRNA gene sequencing and metagenomics to complement the genomics profiling of human samples. To validate our findings, we employ ex vivo lung models, including in vitro functional assays from human lung fluid, fresh explanted lung tissue and blood specimens from patients suffering from COPD, bronchiectasis and allergic asthma. Precision cut lung slices (PCLS) further contribute to our mechanistic investigations. Moreover, we have established both local and international collaborations with experts in animal models of disease. This allows us to assess the translatability of proposed mechanisms and candidate drugs from our human models in vivo.

We currently focus on three major scientific avenues:

  • Immune cell metabolism in COPD: We aim to elucidate how immune cell metabolism influences their functions in COPD. Our focus is on the role of lipids in the trajectory of myeloid cells from early to severe stages, with the goal of harnessing gene expression profiles for designing therapeutics, especially for tissue-resident macrophages.
  • Sex-related immune responses in COPD: Our objective is to comprehensively characterize sex-related differences in the abundance and transcriptomic programs that are active in male and female COPD patients. Exploring the interplay between immune and non-immune alveolar populations is a priority to better understand the origins and mechanistic aspects of the observed differences in clinical manifestations.
  • Heterogeneity of obstructive airway diseases: We are actively working on immunophenotyping bronchiectasis patients in collaboration with the LMU clinics. Our hypothesis is that the immune composition in the lung and periphery of bronchiectasis patients undergoes alterations over the course of the disease. We aim to identify clinical biomarkers distinguishing severity stages and endotypes. Additionally, we investigate how host responses are influenced by changes in the microbiome and how myeloid cells respond to the dysregulation of predominant microbial communities.

If you are interested in joining our interdisciplinary team, we welcome PhD and postdoctoral candidates to reach out to Dr. Kapellos to discuss their scientific interests and potential project ideas.

Scientists at Kapellos Lab

Börner_Lisa_Portrait

Lisa Börner

Bachelor Student
Melo_Letícia_Portrait

Letícya Melo

Postdoc
Primerano_Elias_Portrait

Elias Primerano

PhD Student

Publications

2024, Scientific Article in JCI insight

Interpretable machine learning uncovers epithelial transcriptional rewiring and a role for Gelsolin in COPD.

Transcriptomic analyses have advanced the understanding of complex disease pathophysiology including chronic obstructive pulmonary disease (COPD). However, identifying relevant biologic causative factors has been limited by the integration of high dimensionality data. COPD is characterized by lung destruction and inflammation with smoke exposure being a major risk factor. To define novel biological mechanisms in COPD, we utilized unsupervised and supervised interpretable machine learning analyses of single cell-RNA sequencing data from the gold standard mouse smoke exposure model to identify significant latent factors (context-specific co-expression modules) impacting pathophysiology. The machine learning transcriptomic signatures coupled to protein networks uncovered a reduction in network complexity and novel biological alterations in actin-associated gelsolin (GSN), which was transcriptionally linked to disease state. GSN was altered in airway epithelial cells in the mouse model and in human COPD. GSN was increased in plasma from COPD patients, and smoke exposure resulted in enhanced GSN release from airway cells from COPD patients. This method provides insights into rewiring of transcriptional networks that are associated with COPD pathogenesis and provide a novel analytical platform for other diseases.

Read more
2023, Scientific Article in European Respiratory Journal

The impact of the immune system on lung injury and regeneration in COPD.

COPD is a devastating respiratory condition that manifests via persistent inflammation, emphysema development and small airway remodelling. Lung regeneration is defined as the ability of the lung to repair itself after injury by the proliferation and differentiation of progenitor cell populations, and becomes impaired in the COPD lung as a consequence of cell intrinsic epithelial stem cell defects and signals from the micro-environment. Although the loss of structural integrity and lung regenerative capacity are critical for disease progression, our understanding of the cellular players and molecular pathways that hamper regeneration in COPD remains limited. Intriguingly, despite being a key driver of COPD pathogenesis, the role of the immune system in regulating lung regenerative mechanisms is understudied. In this review, we summarise recent evidence on the contribution of immune cells to lung injury and regeneration. We focus on four main axes: 1) the mechanisms via which myeloid cells cause alveolar degradation; 2) the formation of tertiary lymphoid structures and the production of autoreactive antibodies; 3) the consequences of inefficient apoptotic cell removal; and 4) the effects of innate and adaptive immune cell signalling on alveolar epithelial proliferation and differentiation. We finally provide insight on how recent technological advances in omics technologies and human ex vivo lung models can delineate immune cell-epithelium cross-talk and expedite precision pro-regenerative approaches toward reprogramming the alveolar immune niche to treat COPD.

Read more
2023, Scientific Article in iScience

Mass spectrometry-based autoimmune profiling reveals predictive autoantigens in idiopathic pulmonary fibrosis.

Autoimmunity plays a role in certain types of lung fibrosis, notably connective tissue disease-associated interstitial lung disease (CTD-ILD). In idiopathic pulmonary fibrosis (IPF), an incurable and fatal lung disease, diagnosis typically requires clinical exclusion of autoimmunity. However, autoantibodies of unknown significance have been detected in IPF patients. We conducted computational analysis of B cell transcriptomes in published transcriptomics datasets and developed a proteomic Differential Antigen Capture (DAC) assay that captures plasma antibodies followed by affinity purification of lung proteins coupled to mass spectrometry. We analyzed antibody capture in two independent cohorts of IPF and CTL-ILD patients over two disease progression time points. Our findings revealed significant upregulation of specific immunoglobulins with V-segment bias in IPF across multiple cohorts. We identified a predictive autoimmune signature linked to reduced transplant-free survival in IPF, persisting over time. Notably, autoantibodies against thrombospondin-1 were associated with decreased survival, suggesting their potential as predictive biomarkers.

Read more
2023, Scientific Article in Nature medicine

An integrated cell atlas of the lung in health and disease.

Single-cell technologies have transformed our understanding of human tissues. Yet, studies typically capture only a limited number of donors and disagree on cell type definitions. Integrating many single-cell datasets can address these limitations of individual studies and capture the variability present in the population. Here we present the integrated Human Lung Cell Atlas (HLCA), combining 49 datasets of the human respiratory system into a single atlas spanning over 2.4 million cells from 486 individuals. The HLCA presents a consensus cell type re-annotation with matching marker genes, including annotations of rare and previously undescribed cell types. Leveraging the number and diversity of individuals in the HLCA, we identify gene modules that are associated with demographic covariates such as age, sex and body mass index, as well as gene modules changing expression along the proximal-to-distal axis of the bronchial tree. Mapping new data to the HLCA enables rapid data annotation and interpretation. Using the HLCA as a reference for the study of disease, we identify shared cell states across multiple lung diseases, including SPP1+ profibrotic monocyte-derived macrophages in COVID-19, pulmonary fibrosis and lung carcinoma. Overall, the HLCA serves as an example for the development and use of large-scale, cross-dataset organ atlases within the Human Cell Atlas.

Read more

Contact

Theodoros Kapellos LHI

Dr. Theodoros Kapellos

Team Leader